Plasma homocysteine and the risk of venous thromboembolism: Insights from the FIELD study

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 12, 2012, Pages 2213-2219

  Herrmann, Markus ^a,b   Whiting, Malcolm J ^c   Veillard, Anne Sophie ^d   Ehnholm, Christian ^e   Sullivan, David R ^a   Keech, Anthony C ^d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b CENTRAL HOSPITAL OF BOLZANO   (Italy)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e BIOMEDICUM HELSINKI   (Finland)

Author keywords

Diabetes mellitus; Fenofibrate; Homocysteine; Pulmonary embolism; Thrombosis

Indexed keywords

APOLIPOPROTEIN A2; CREATININE; FENOFIBRATE; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN A; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FEMALE; FENOFIBRATE; HOMOCYSTEINE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; PLACEBOS; PROPORTIONAL HAZARDS MODELS; VENOUS THROMBOEMBOLISM;

EID: 84872833486     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0078     Document Type: Article

References (47)

1. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011;17:1410-22.
2. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-81.
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
4. Biasucci LM, Biasillo G, Stefanelli A. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clin Chem Lab Med 2010;48:1685-91.
5. Lippi G, Favaloro EJ, Montagnana M, Franchini M. C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med 2010;48:1693-701.
6. McCullough PA, Ahmed AB, Zughaib MT, Glanz ED, Di Loreto MJ. Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events. Rev Cardiovasc Med 2011;12:173-85.
7. Steiner G. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD. Cardiovasc Drugs Ther 2009;23:403-8.
8. Keating GM. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Am J Cardiovasc Drugs 2011;11:227-47.
9. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
10. Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, et al. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 2009;29:950-5.
11. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
12. den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005;3:292-9.
13. Bozic-Mijovski M. Hyperhomocysteinemia and thrombophilia. Clin Chem Lab Med 2010;48(Suppl 1):S89-95.
14. Quere I, Chasse JF, Dupuy E, Bellet E, Molho-Sabatier P, Tobelem G, et al. [Homocysteine, 5,10-methylenetetrahydrofolate reductase and deep venous thrombosis. Survey of 120 patients in internal medicine]. Rev Med Interne 1998;19: 29-33.
15. Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci PM. Low plasma levels of vitamin B(6) are independently associated with a heightened risk of deep-vein thrombosis. Circulation 2001;104:2442-6.
16. Gemmati D, Previati M, Serino ML, Moratelli S, Guerra S, Capitani S, et al. Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects. Arterioscler Thromb Vasc Biol 1999;19:1761-7.
17. de Franchis R, Fermo I, Mazzola G, Sebastio G, Di Minno G, Coppola A, et al. Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. Thromb Haemost 2000;84:576-82.
18. Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb 2002;32:51-8.
19. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. Cardiovasc Diabetol 2004;3:9.
20. Lee KL, Harrell FE Jr., Tolley HD, Rosati RA. A comparison of test statistics for assessing the effects of concomitant variables in survival analysis. Biometrics 1983;39:341-50.
21. de Bree A, van der Put NM, Mennen LI, Verschuren WM, Blom HJ, Galan P, et al. Prevalences of hyperhomocysteinemia, unfavorable cholesterol profile and hypertension in European populations. Eur J Clin Nutr 2005;59:480-8.
22. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
23. Royston P, Altman DG. Regression using fractional polynomials of continuous covariates - parsimonious parametric modeling. Appl Stat-J Roy St C 1994;43:429-67.
24. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-82.
25. Tsai AW, Cushman M, Tsai MY, Heckbert SR, Rosamond WD, Aleksic N, et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol 2003;72:192-200.
26. Loscalzo J. Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology. J Clin Invest 2009;119:3203-5.
27. Cattaneo M. Hyperhomocysteinemia and venous thromboembolism. Semin Thromb Hemost 2006;32:716-23.
28. Jacovina AT, Deora AB, Ling Q, Broekman MJ, Almeida D, Greenberg CB, et al. Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis. J Clin Invest 2009;119:3384-94.
29. Colucci M, Cattaneo M, Martinelli I, Semeraro F, Binetti BM, Semeraro N. Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. J Thromb Haemost 2008;6:1571-7.
30. De Stefano V, Casorelli I, Rossi E, Zappacosta B, Leone G. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Semin Thromb Hemost 2000;26:305-11.
31. Samuelsson O, Lee DM, Attman PO, Knight-Gibson C, Mullen JK, Larsson R, et al. The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression. Nephron 1999;82:306-11.
32. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999;55:1028-35.
33. van Guldener C. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrol Dial Transplant 2006;21:1161-6.
34. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:280-90.
35. Luc G, Jacob N, Bouly M, Fruchart JC, Staels B, Giral P. Fenofibrate increases homocystinemia through a PPARalphamediated mechanism. J Cardiovasc Pharmacol 2004;43: 452-3.
36. Krysiak R, Handzlik G, Okopien B. Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose. Pharmacol Rep 2010;62:1099-107.
37. Krysiak R, Okopien B. The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report. Atherosclerosis 2010;213:325-8.
38. Lacut K, Le Gal G, Abalain JH, Mottier D, Oger E. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? Thromb Res 2008;122:314-9.
39. Silvestri E, de Lange P, Moreno M, Lombardi A, Ragni M, Feola A, et al. Fenofibrate activates the biochemical pathways and the de novo expression of genes related to lipid handling and uncoupling protein-3 functions in liver of normal rats. Biochim Biophys Acta 2006;1757:486-95.
40. Montanaro MA, Bernasconi AM, Gonzalez MS, Rimoldi OJ, Brenner RR. Effects of fenofibrate and insulin on the biosynthesis of unsaturated fatty acids in streptozotocin diabetic rats. Prostaglandins Leukot Essent Fatty Acids 2005;73: 369-78.
41. Montanaro MA, Gonzalez MS, Bernasconi AM, Brenner RR. Role of liver X receptor, insulin and peroxisome proliferator activated receptor alpha on in vivo desaturase modulation of unsaturated fatty acid biosynthesis. Lipids 2007;42:197-210.
42. Aslibekyan S, Kabagambe EK, Irvin MR, Straka RJ, Borecki IB, Tiwari HK, et al. A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenet Genomics 2012;22:191-7.
43. Delluc A, Malecot JM, Kerspern H, Nowak E, Carre JL, Mottier D, et al. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism. Atherosclerosis 2012;220:184-8.
44. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
45. Agarwal V, Phung OJ, Tongbram V, Bhardwaj A, Coleman CI. Statin use and the prevention of venous thromboembolism: a meta-analysis. Int J Clin Pract 2010;64:1375-83.
46. Pai M, Evans NS, Shah SJ, Green D, Cook D, Crowther MA. Statins in the prevention of venous thromboembolism: a metaanalysis of observational studies. Thromb Res 2011;128: 422-30.
47. Mayer O Jr., Simon J, Holubec L, Pikner R, Subrt I. Fenofibrateinduced hyperhomocysteinemia may be prevented by folate coadministration. Eur J Clin Pharmacol 2003;59:367-71.